| Metadata |
| datasetIdentifier | PASS01332 |
| datasetType | SRM |
| submitter | Axel Ducret <axel.ducret@roche.com> |
| submitter_organization | F. Hoffmann-La Roche Ltd |
| lab_head_full_name | Todd Hembrough |
| lab_head_email | todd.hembrough@nantomics.com |
| lab_head_organization | OncoplexDX |
| lab_head_country | USA |
| datasetTag | 5pr_FFPE_lumr_ClDev |
| datasetTitle | SRM clinical development set for the 5-protein signature predictive for lumretuzumab in FFPE xenograft (10 responders, 19 non-responders). Support for data presented in Fig. 2 and S5 Table |
| publicReleaseDate | 2019-03-08 00:00:00 |
| finalizedDate | 2019-02-03 08:17:55 |
| summary | |
| contributors | Axel Ducret, Ian James, Sabine Wilson, Martina Feilke, Andreas Tebbe, Nikolaj Dybowski, Sarah Elschenbroich, Martin Klammer, Adele Blackler, Wei-Li Liao, Yuan Tian, Thomas Friess, Birgit Bossenmaier, Gabriele Dietmann, Christoph Schaab, Todd Hembrough, Maurizio Ceppi |
| publication | Axel Ducret, Ian James, Sabine Wilson, Martina Feilke, Andreas Tebbe, Nikolaj Dybowski, Sarah Elschenbroich, Martin Klammer, Adele Blackler, Wei-Li Liao, Yuan Tian, Thomas Friess, Birgit Bossenmaier, Gabriele Dietmann, Christoph Schaab, Todd Hembrough, Maurizio Ceppi, Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial, PLOSOne, submitted. |
| growth | |
| treatment | |
| extraction | |
| separation | |
| digestion | |
| acquisition | |
| informatics | |
| instruments | Thermo Scientific Quantiva |
| species | human |
| massModifications | none |
